

**OptiBiotix Health plc  
("OptiBiotix" or the "Company" or "the Group")**

**First order from leading US weight management brand**

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces it has received its first order from a leading weight management brand in the United States of America ("USA").

The order is for SlimBiome® as an ingredient which will be incorporated into a range of flavoured drinks, similar to SlimBiome Medical, which reduces hunger. The products will be included in one of the USA's leading weight management brands. SlimBiome® has undergone multiple human studies which show its ability to reduce hunger and food cravings which leads to lower calorie intake. OptiBiotix has been working with this brand for over 18 months to carry out human studies which allows the brand to make health claims of hunger control on its products in the USA. Scientifically substantiated health claims help to differentiate these products from others on the market. In the changing landscape of this market, brought about by the anti-obesity drugs, consumers are actively looking for natural, science backed appetite support products. SlimBiome® meets this developing trend.

OptiBiotix expect further orders for a second product, a tablet containing SlimBiome®, within H1 2025. Whilst it is too early to understand the potential scale of the opportunity, this news is material in that it represents the inclusion of SlimBiome® in products of one of the USA's most popular weight management brands. Further information on the partner and brand will be announced on launch which the Company anticipates will be in H1 2025. However, the Company reminds investors that launch timescales are dictated by the brand owner and these can be subject to change.

**Stephen O'Hara, CEO of OptiBiotix Health plc said** *"We are pleased to announce the first order for the use of SlimBiome® in one of the USA's leading weight management brands. The use of SlimBiome® has allowed the brand to make health claims of hunger control on its products which differentiate them from other products on the market. We anticipate more orders and product launches with this brand as it extends the range of products containing SlimBiome® in the USA market in 2025."*

*"Following the launch of the anti-obesity drugs, natural non-drug alternatives to reduce hunger and cravings are actively being sought by consumers. This announcement demonstrates that the science and multiple human studies carried out on SlimBiome® is now attracting the interest of major brands around the world."*

The Directors of the Company are responsible for the release of this announcement.

**For further information, please contact:**

**OptiBiotix Health plc**  
Neil Davidson, Chairman  
Stephen O'Hara, Chief Executive

[www.optibiotix.com](http://www.optibiotix.com)  
Contact via Walbrook below

**Cairn Financial Advisers LLP (NOMAD)**  
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

**Peterhouse Capital Limited (Broker)**  
Duncan Vasey / Lucy Williams

Tel: 020 7220 9797

**Walbrook PR Ltd**  
Anna Dunphy

Mob: 07876 741 001

About OptiBiotix - [www.optibiotix.com](http://www.optibiotix.com)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@lse.com](mailto:rs@lse.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCIIMATMTIBBAA